|
2004 Conference Publication Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administrationMann, HJ, Demmon, SL, Boelk, DA, Payne, CA, Effron, MB, Rajagopalan, N, Williams, MD, Beck, GM and Gopalrathnam, G (2004). Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. 38th Midyear Clinical Meeting of the American-Society-of-Health-System-Pharmacists, New Orleans La, Dec 08-09, 2003. BETHESDA: AMER SOC HEALTH-SYSTEM PHARMACISTS. doi: 10.1093/ajhp/61.24.2664 |
|
2004 Conference Publication Safety of drotrecogin alfa (activated): Results of Xeus, a prospective multicenter observational studyKaren, S, Lipsett, P, Effron, M, Rickert, T, Zeckel, M, Linde-Zwirble, W, Steingrub, J and Cheatham, M (2004). Safety of drotrecogin alfa (activated): Results of Xeus, a prospective multicenter observational study. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.724S-a |
|
2004 Conference Publication Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patientsRickert, T, Jay, S, Michael, C, Karen, S, Pamela, L, Effron, M, Linde-Zwirble, W and Zeckel, M (2004). Clinical use of drotrecogin alfa (activated): Patients treated in the XEUS study differ from high risk prowess patients. CHEST 2004 Conference, Seattle Wa, Oct 23-28, 2004. NORTHBROOK: AMER COLL CHEST PHYSICIANS. doi: 10.1378/chest.126.4_MeetingAbstracts.865S-a |
|
2004 Journal Article Final results of the ReoPro Readministration RegistryDery, JP, Braden, GA, Lincoff, AM, Kereiakes, DJ, Browne, K, Little, T, George, BS, Sane, DC, Cines, DB, Effron, MB, Mascelli, MA, Langrall, MA, Damaraju, L, Barnathan, ES and Tcheng, JE (2004). Final results of the ReoPro Readministration Registry. American Journal of Cardiology, 93 (8), 979-984. doi: 10.1016/j.amjcard.2003.12.051 |
|
2003 Journal Article Feasibility and implications of an early discharge strategy after percutaneous intervention with Abciximab in acute myocardial infarction (the CADILLAC trial)Kandzari, DE, Tcheng, JE, Cohen, DJ, Bakhai, A, Grines, CL, Cox, DA, Effron, M, Stuckey, T, Griffin, JJ, Turco, M, Carroll, JD, Fahy, M, Mehran, R and Stone, GW (2003). Feasibility and implications of an early discharge strategy after percutaneous intervention with Abciximab in acute myocardial infarction (the CADILLAC trial). American Journal of Cardiology, 92 (7), 779-784. doi: 10.1016/S0002-9149(03)00882-8 |
|
2003 Journal Article Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trialTcheng, JE, Kandzari, DE, Grines, CL, Cox, DA, Effron, MB, Garcia, E, Griffin, JJ, Guagliumi, G, Stuckey, T, Turco, M, Fahy, M, Lansky, AJ, Mehran, R and Stone, GW (2003). Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation, 108 (11), 1316-1323. doi: 10.1161/01.CIR.0000087601.45803.86 |
|
2003 Conference Publication Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trialKandzari, DE, Tcheng, JE, Grines, CL, Effron, M, Cox, DA, Garcia, E, Griffin, JJ, Guagliumi, G, Stuckey, TD, Turco, M, Lansky, AJ, Mehran, R and Stone, GW (2003). Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC. |
|
2003 Conference Publication Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trialKandzari, DE, Tcheng, JE, Grines, CL, Cohen, DJ, Bakhai, A, Cox, DA, Stuckey, TD, Effron, M, Griffin, JJ, Turco, M, Carroll, JD, Fahy, M, Mehran, R and Stone, GW (2003). Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC. |
|
2003 Conference Publication Abciximab readministration: Final results of the Reopro(fi) read ministration registryDery, JP, Braden, GA, Lincoff, AM, Kereiakes, DJ, Browne, KF, Little, T, George, BS, Effron, MB, Mascelli, MA, Langrall, MA, Damaraju, L, Barnathan, ES and Tcheng, JE (2003). Abciximab readministration: Final results of the Reopro(fi) read ministration registry. 52nd Annual Scientific Session of the American-College-of-Cardiology, Chicago Illinois, Mar 30-Apr 02, 2003. NEW YORK: ELSEVIER SCIENCE INC. |
|
2002 Conference Publication Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trialBakhai, A, Stone, GW, Murphy, SA, Githiora, L, Berezin, RH, Gedney, S, Hormel, P, Effron, M, Cox, DA, Tcheng, JE, Grines, CL and Cohen, DJ (2002). Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial. American-Heart-Association Abstracts From Scientific Sessions, Chicago Illinois, Nov 17-20, 2002. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2002 Conference Publication Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery diseasePatterson, D, MacDonald, TM, Effron, MB, Emmick, JT, Mitchell, MI and Kloner, RA (2002). Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. American-Heart-Association Abstracts From Scientific Sessions, Chicago Illinois, Nov 17-20, 2002. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2001 Conference Publication A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical dataKennedy, JS, Bymaster, FP, Schuh, L, Calligaro, DO, Nomikos, G, Felder, CC, Bernauer, M, Kinon, BJ, Baker, RW, Hay, D, Roth, HJ, Dossenbach, M, Kaiser, C, Beasley, CM, Holcombe, JH, Effron, MB and Breier, A (2001). A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Symposium on Management of Psychoses in Older People, Barcelona Spain, Nov, 2000. W SUSSEX: JOHN WILEY & SONS LTD. doi: 10.1002/1099-1166(200112)16:1+3.0.CO;2-5 |
|
2001 Conference Publication Abciximab readministration - Results of the ReoPro readministration registryTcheng, JE, Kereiakes, DJ, Lincoff, AM, George, BS, Kleiman, NS, Sane, DC, Cines, DB, Jordan, RE, Mascelli, MA, Langrall, MA, Damaraju, L, Schantz, A, Effron, MB and Braden, GA (2001). Abciximab readministration - Results of the ReoPro readministration registry. 71st Scientific Session of the American-Heart-Association, Dallas Tx, Nov 08-12, 1998. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1161/hc3301.094533 |
|
2001 Conference Publication Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trialTcheng, JE, Effron, M, Grines, CL, Garcia, E, Cox, D, Stuckey, T, Carroll, J, Guagliumi, G, Rutherford, B, Lansky, AJ, Esente, P, Griffin, J and Stone, GW (2001). Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trial. NEW YORK: ELSEVIER SCIENCE INC. |
|
2001 Conference Publication A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trialStone, GW, Grines, CL, Cox, DA, Garcia, E, Tcheng, JE, Stuckey, T, Carroll, J, Guagliumi, G, Rutherford, B, Johnson, G, Effron, M, Esente, P, Lansky, AJ and Griffin, J (2001). A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. NEW YORK: ELSEVIER SCIENCE INC. |
|
2000 Conference Publication Abciximab improves outcomes in patients of all ages: Pooled analysis of 4 phase 3 trialsEffron, MB, Booth, J, Balog, C and Cabot, C (2000). Abciximab improves outcomes in patients of all ages: Pooled analysis of 4 phase 3 trials. NEW YORK: EXCERPTA MEDICA INC. |
|
2000 Journal Article Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventionsKleiman, NS, Grazeiadei, N, Maresh, K, Taylor, RJ, Frederick, B, Lance, ET, Effron, MB, Jordan, RE and Mascelli, MA (2000). Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. American Heart Journal, 140 (3), 492-501. doi: 10.1067/mhj.2000.109220 |
|
2000 Journal Article Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trialsLincoff, AM, LeNarz, LA, Despotis, GJ, Smith, PK, Booth, JE, Raymond, RE, Sapp, SK, Cabot, CF, Tcheng, JE, Califf, RM, Effron, MB and Topol, EJ (2000). Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials. Annals of Thoracic Surgery, 70 (2), 516-526. doi: 10.1016/S0003-4975(00)01343-6 |
|
2000 Conference Publication Comparison of GP IIb/IIIa receptor inhibitors in patients undergoing percutaneous coronary interventions: a meta-analysisChadbourne, EB, Allen, IE, Luo, D, Gordon, MJ, Reid, P, Wilson, MG, Effron, MB, Perkins, LE, Jamal, HH and Ross, SD (2000). Comparison of GP IIb/IIIa receptor inhibitors in patients undergoing percutaneous coronary interventions: a meta-analysis. LONDON: W B SAUNDERS CO LTD. |
|
2000 Journal Article Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplastyFredrickson, BJ, Turner, NA, Kleiman, NS, Graziadei, N, Maresh, K, Mascelli, MA, Effron, MB and McIntire, LV (2000). Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation, 101 (10), 1122-1129. doi: 10.1161/01.CIR.101.10.1122 |
